Sugi Predict

Sugi Predict / Compounds / SCHEMBL1852201

SCHEMBL1852201

SCHEMBL1852201

NC(=O)[C](Cl)c1cc2ccccc2[nH]1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 4/20 0.62
▸ KDM4E B2RXH2 4/20 0.61
▸ HSD17B10 Q99714 2/20 0.61
▸ MAPT P10636 1/20 0.61
▸ DAO P14920 1/20 0.61
▸ HPGD P15428 1/20 0.61
▸ SRD5A2 P31213 1/20 0.61
▸ ALDH1A1 P00352 1/20 0.58
▸ GAA P10253 1/20 0.58
▸ MAPK1 P28482 1/20 0.58
▸ LMNA P02545 2/20 0.51
▸ PDGFRB P09619 2/20 0.51
▸ PDGFRA P16234 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ IDO1 P14902 1/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ TP53 P04637 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ HRH4 Q9H3N8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2080470 0.82 FLT3 (0.67) FLT3KDM4EHSD17B10MAPTDAO
SCHEMBL29890869 0.82 FLT3 (0.71) FLT3KDM4EHSD17B10MAPTDAO
SCHEMBL29362757 0.82 FLT3 (0.71) FLT3KDM4EHSD17B10MAPTDAO
SCHEMBL118686 0.82 FLT3 (0.71) FLT3KDM4EHSD17B10MAPTDAO
SCHEMBL2721054 0.82 FLT3 (0.71) FLT3KDM4EHSD17B10MAPTDAO
Hydrochloric Acid SCHEMBL20569802 0.80 FLT3 (0.69) FLT3KDM4EHSD17B10MAPTDAO
Hydrochloric Acid SCHEMBL30071329 0.80 FLT3 (0.69) FLT3KDM4EHSD17B10MAPTDAO
Bromide SCHEMBL6056708 0.80 FLT3 (0.69) FLT3KDM4EHSD17B10MAPTDAO
Hydrochloric Acid SCHEMBL6073131 0.80 FLT3 (0.69) FLT3KDM4EHSD17B10MAPTDAO
Hydrochloric Acid SCHEMBL16463892 0.80 FLT3 (0.69) FLT3KDM4EHSD17B10MAPTDAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 — — US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 — — EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 — — US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 — — WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
WO-2009071888-A1 PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 — — EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA FLT3 347/4885KDM4E 2802/4885HSD17B10 2438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.